On Wednesday, the Minister of Health, Enrique Paris, announced that Chile will join the inoculation of a booster dose in the vaccination process against Covid19, targeting in the first instance, those people who reached a lower immune response.
In this context, the academic of the Department of Clinical Biochemistry and Immunohematology of the University of Talca, Marcelo Alarcón, highlighted as positive the confirmation of this third dose, especially for those people who have chronic or immunocompromised diseases, such as diabetes or cancer.
“The immune response of these patients, compared to a normal person, is much lower, therefore it is important that this third dose is applied considering that there are international studies that support it. It has been observed that with this additional inoculation could even double the rate of antibodies generated, “said the specialist.
Alarcon said that the ideal in this booster dose is that it is a different vaccine than the one that was already inoculated in the initial scheme of two doses (Pfizer, Coronavac or AstraZeneca) or single dose (Janssen or CanSino).
This is because “the immune system is used to generating a response in the generation of antibodies, but by placing a different booster dose what is produced is to overstimulate in a greater way the production of antibodies, that is, a much greater response against the Coronavirus is generated in the body”.
According to Minister Paris, the specific definition of the groups to which this new vaccination process will target and the dates on which it will be carried out, must be defined in conjunction with President Sebastián Piñera and a team of experts.
